相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical utility of circulating tumor cells: an update
Antoine Vasseur et al.
MOLECULAR ONCOLOGY (2021)
Molecular characterization of circulating tumour cells identifies predictive markers for outcome in primary, triple-negative breast cancer patients
Ann-Kathrin Bittner et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions
Fabienne Schochter et al.
CELLS (2019)
Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis
Jaehag Jung et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Circulating Tumor Cells: Diagnostic and Therapeutic Applications
Eric Lin et al.
ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, VOL 20 (2018)
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial
M. Ignatiadis et al.
ANNALS OF ONCOLOGY (2018)
Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients
Sofia Agelaki et al.
ONCOTARGET (2017)
Circulating tumor cells: clinical validity and utility
Luc Cabel et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2017)
The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial
B. A. S. Jaeger et al.
PLOS ONE (2017)
Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients
Bahriye Aktas et al.
BMC CANCER (2016)
Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review
C. Yeung et al.
CANCER AND METASTASIS REVIEWS (2016)
Early dissemination seeds metastasis in breast cancer
Hedayatollah Hosseini et al.
NATURE (2016)
Comparison of HER2 Expression in Primary Tumor and Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients
Brigitte Rack et al.
ONCOLOGY (2016)
Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor
Nick Beije et al.
NEOPLASIA (2016)
Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy
Sabine Kasimir-Bauer et al.
BREAST CANCER RESEARCH (2016)
The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients
Markus Wallwiener et al.
BMC CANCER (2015)
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity
Wedad M. Hanna et al.
MODERN PATHOLOGY (2014)
Technologies for detection of circulating tumor cells: facts and vision
Catherine Alix-Panabieres et al.
LAB ON A CHIP (2014)
Breast cancer intra-tumor heterogeneity
Luciano G. Martelotto et al.
BREAST CANCER RESEARCH (2014)
The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse
A. D. Hartkopf et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab
Suthinee Ithimakin et al.
CANCER RESEARCH (2013)
HER2 discordance between primary and metastatic breast cancer: Assessing the clinical impact
Natalie H. Turner et al.
CANCER TREATMENT REVIEWS (2013)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Heterogeneity of Estrogen Receptor Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients
Anna Babayan et al.
PLOS ONE (2013)
Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study
V. Georgoulias et al.
ANNALS OF ONCOLOGY (2012)
Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients
Brigitte Rack et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2012)
Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies
Eitan Amir et al.
CANCER TREATMENT REVIEWS (2012)
Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
Linda Sofie Lindstrom et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Frequency of HER2 Heterogeneity by Fluorescence In Situ Hybridization According to CAP Expert Panel Recommendations Time for a New Look at How to Report Heterogeneity
Kimberly H. Allison et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients
Bahriye Aktas et al.
GYNECOLOGIC ONCOLOGY (2011)
HER2-Positive Circulating Tumor Cells in Breast Cancer
Michail Ignatiadis et al.
PLOS ONE (2011)
HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial
Tanja Fehm et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Changes of HER2 Status in Circulating Tumor Cells Compared With the Primary Tumor During Treatment for Advanced Breast Cancer
Elisabetta Munzone et al.
CLINICAL BREAST CANCER (2010)
Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial
Sabine Riethdorf et al.
CLINICAL CANCER RESEARCH (2010)
Targeting Breast Cancer Stem Cells
Suling Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)
Alastair M. Thompson et al.
BREAST CANCER RESEARCH (2010)
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer
C. Liedtke et al.
ANNALS OF ONCOLOGY (2009)
Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
C. Simmons et al.
ANNALS OF ONCOLOGY (2009)
Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies
Mitra Tewes et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients
Marta Pestrin et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells
Tanja Fehm et al.
BREAST CANCER RESEARCH (2009)
HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy
Alfredo Santinelli et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients
Tanja Fehm et al.
BREAST CANCER RESEARCH (2008)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients
Erich F. Solomayer et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Histopathologic characteristics predicting HER-2/neu amplification in breast cancer
R Prati et al.
BREAST JOURNAL (2005)
Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab
N Dybdal et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques
CM Ellis et al.
JOURNAL OF CLINICAL PATHOLOGY (2005)
Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas
I Vanden Bempt et al.
HISTOPATHOLOGY (2005)
Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer
C Lottner et al.
JOURNAL OF PATHOLOGY (2005)
HER-2 testing in breast cancer using parallel tissue-based methods
H Yaziji et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
HER-2 gene amplification can be acquired as breast cancer progresses
SD Meng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification
P Lal et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2003)
HER-2/neu analysis in archival tissue samples of human breast cancer:: Comparison of immunohistochemistry and fluorescence in situ hybridization
A Lebeau et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
